MTOR and breast cancer: The mTOR inhibitors rapamycin and rapamycin analogues (CCI-779, RAD001, and AP23573) have exhibited impressive growth inhibitory effects against a broad range of human cancers, including breast cancer, in preclinical and early clinical studies (Chan, 2004; Vignot et al, 2005).